Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18683555 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18391716 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL28257150 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL25688662 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL11283293 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL17538638 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18683565 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL30156363 | 0.95 | TSHR (0.33) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL16207199 | 0.93 | TSHR (0.35) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL28177955 | 0.92 | CYP1A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| EP-4358936-A1 | NUCLEIC ACID CONTAINING NANOPARTICLES | Bio-TRIP B.V. (NL) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024073588-A1 | RESPIRATORY DRY POWDER DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-117545467-A | Nucleic acid-containing nanoparticles | 比奥-特里普公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2011089595-A2 | SUSTAINED-RELEASE NUCLEIC ACID MATRIX COMPOSITIONS | POLYPID LTD. (IL) | 2011-07-28 | — | — | WO | disclosed |
| US-20110117197-A1 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION | POLYPID LTD. (IL) | 2011-05-19 | — | — | US | disclosed |
| US-20110117197-A1 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION | POLYPID LTD. (IL) | 2011-05-19 | — | — | US | disclosed |
| WO-2011007353-A1 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION | POLYPID LTD. (IL) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010113157-A1 | LIPOPEPTIDE INHIBITORS OF HIV-1 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-10-07 | — | — | WO | disclosed |
| US-20100093682-A1 | LIPID COMPOSITION HAVING EXCELLENT SHAPE RETENTION PROPERTY AND PRODUCT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093682-A1 | LIPID COMPOSITION HAVING EXCELLENT SHAPE RETENTION PROPERTY AND PRODUCT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-1448069-B1 | DETERIORATION PREVENTIVE AGENT | TAKASAGO PERFUMERY CO LTD (JP) | 2009-06-03 | — | — | EP | disclosed |
| US-7342004-B2 | Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds | STERIX LTD. (GB) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093682-A1 | LIPID COMPOSITION HAVING EXCELLENT SHAPE RETENTION PROPERTY AND PRODUCT | MGLL, LIPC, CETP | MAPT 63/4885CA12 3139/4885GMNN 2117/4885 |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | LIPA, LIPC, TLR9 | MAPT 3510/4885CA12 3983/4885GMNN 945/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MAPT 1993/4885CA12 986/4885GMNN 2103/4885 |
| US-20110117197-A1 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION | LIPA, LIPC, ABCB11 | MAPT 3001/4885CA12 2319/4885GMNN 1786/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | MAPT 1927/4885CA12 2178/4885GMNN 1426/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | MAPT 2479/4885CA12 1787/4885GMNN 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.